接受异基因造血干细胞移植患者晚期移植相关血栓性微血管病的特征
该回顾性研究分析了1451例异基因造血干细胞移植受者中早期(≤100天)与晚期(>100天)移植相关血栓性微血管病(TA-TMA)的危险因素与结局。早期TA-TMA 45例(3.1%),中位发生时间27天;晚期39例(2.7%),中位303天。早期患者更常见高钙调神经磷酸酶抑制剂血药浓度和急性GVHD,晚期患者更常见慢性GVHD。TMA改善者中位总生存未达到,未改善者仅2个月(P<.001)。
要点
- 早期TA-TMA 45例(3.1%),中位27天;晚期39例(2.7%),中位303天。
- 早期TA-TMA与高钙调神经磷酸酶抑制剂血药浓度及急性GVHD相关(P<.001)。
- 晚期TA-TMA与慢性GVHD相关(P<.001);TMA改善者生存显著优于未改善者(P<.001)。
核心结论
- 早期和晚期TA-TMA的死亡率均仍高得不可接受。
- 未来需要针对早期诊断、触发因素识别和靶向治疗开展研究。
研究设计与样本
- 回顾性研究,纳入1451例异基因造血干细胞移植受者,分析早期(≤100天)与晚期(>100天)TA-TMA的危险因素和结局。
主要发现
- 早期TA-TMA发生于45例(3.1%),中位发生时间27天(范围3-91天);晚期TA-TMA发生于39例(2.7%),中位发生时间303天(范围122-2595天)。
- 早期TA-TMA患者更常见高钙调神经磷酸酶抑制剂血药浓度(P<.001)和急性移植物抗宿主病(GVHD,P<.001);晚期TA-TMA患者更常见慢性GVHD(P<.001)。
- 整个队列TMA起病后估计中位总生存为6个月;TMA改善者估计中位总生存未达到,而未改善者为2个月(P<.001)。
- 早期TA-TMA组多因素分析中,年龄较大(每增加10岁,HR 1.40;95%CI 1.00-1.94;P=.049)和细菌感染(HR 2.42;95%CI 0.98-6.00;P=.056)与死亡率正相关;转换为MMF治疗(HR 0.40;95%CI 0.16-0.99;P=.047)和TMA改善(HR 0.08;95%CI 0.03-0.25;P<.001)与死亡率负相关。
- 晚期TA-TMA组中,TMA改善是唯一与较低死亡风险独立相关的预测因素(HR 0.05;95%CI 0.02-0.19;P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transplant-associated thrombotic microangiopathy (TA-TMA) has a wide range of presentations after hematopoietic stem-cell transplantation (HSCT). We retrospectively studied the risk factors and outcomes of patients with early (≤day 100) and late (>day 100) TA-TMA. Among the 1451 HSCT recipients, early TA-TMA occurred in 45 (3.1%) patients at a median of 27 (3-91) days, and late TA-TMA in 39 (2.7%) patients at a median of 303 (122-2595) days. Patients with early TA-TMA were more likely to have high blood calcineurin-inhibitor levels (P < .001) and acute graph-vs-host disease (GVHD, P < .001), while late TMA patients were more likely to have chronic GVHD (P < .001). The estimated median overall survival after onset of TMA for the entire cohort was 6 months. The estimated median overall survival was not reached in patients with an improvement of TMA vs 2 months in patients with no improvement (P < .001). In the early TMA group, older age (for every 10 years, HR 1.40; 95% CI 1.00-1.94; P = .049) and bacterial infection (HR 2.42; 95% CI 0.98-6.00; P = .056) were positively associated with mortality. Switching to MMF treatment (HR 0.40; 95% CI 0.16-0.99; P = .047) and improvement of TMA (HR 0.08; 95% CI 0.03-0.25; P < .001) were negatively associated with mortality in the multivariate analysis. In the late TMA group, the improvement of TMA was the only independent predictor associated with a lower risk of death (HR 0.05; 95% CI 0.02-0.19; P < .001). Mortality rates in both early and late TMA remain unacceptably high. Future studies are needed for early diagnosis, trigger identifications, and use of targeted treatments.
引用
- Heybeli C, Sridharan M, Alkhateeb HB, et al. Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2020. PMID: 32618000. doi:10.1002/ajh.25922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。